Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravitreal KSI-301 versus sham in moderately severe to severe non-proliferative diabetic retinopathy
2020-001064-29Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tarcocimab tedromer in nonproliferative diabetic retinopathy (NPDR) and diabetic retinopathy (DR) (2 arms), sponsored by Kodiak Sciences. Primary endpoint: Proportion of eyes improving at least 2 steps on DRSS from baseline at Week 48. Started Jul 2021; status: terminated.
02
Drugs
tarcocimab tedromer
03
Conditions
nonproliferative diabetic retinopathy (NPDR)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2020-001064-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001064-29.